Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Ozempic vs. Mounjaro:: Battle of the bulge
10:16am, Monday, 04'th Dec 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Nov
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
09:00am, Monday, 04'th Dec 2023
Modern portfolio theory offers investors some important guidelines for picking the best potential dividend stocks. Eli Lilly meets all of the theory's most important guideposts.
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
07:43am, Monday, 04'th Dec 2023
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15
07:21am, Monday, 04'th Dec 2023
Eli Lilly , on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the rad
3 No-Brainer Growth Stocks to Buy in December
06:54am, Sunday, 03'rd Dec 2023
Eli Lilly's weight-loss drug Zepbound should be a game changer. Novo Nordisk's momentum, driven by Ozempic and Wegovy, will likely keep going.
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
05:53am, Saturday, 02'nd Dec 2023
Lilly's Mounjaro and Zepbound appear to have an efficacy advantage over Novo Nordisk's Ozempic and Wegovy. Lilly also has a stronger product lineup and pipeline outside of the diabetes and obesity ind
5 Top Stocks to Buy Before 2024
05:00am, Saturday, 02'nd Dec 2023
Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- ar
US FDA gives second approval to Eli Lilly's drug for type of blood cancer
06:18pm, Friday, 01'st Dec 2023
Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer.
There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen
12:22pm, Friday, 01'st Dec 2023
Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, an
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:31am, Friday, 01'st Dec 2023
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
1 Underrated Reason to Buy Eli Lilly Stock
09:45am, Friday, 01'st Dec 2023
The shares have vaulted as a result of its recently approved weight-loss drug. But it also pays a dividend, which has increased steadily over the years.
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
08:29am, Friday, 01'st Dec 2023
Some leading U.S. obesity specialists say they expect Eli Lilly's powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk's popular Wegovy as they belong to
Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy Program
01:19pm, Thursday, 30'th Nov 2023
Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to atherosc
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
05:26am, Thursday, 30'th Nov 2023
A large analysis of electronic health records shows a strong advantage for Eli Lilly's weight management treatment tirzepatide. Patients given tirzepatide were more than twice as likely to achieve a 1
4 Large Drug Stocks to Watch as IBD Market Gains Traction
11:20am, Wednesday, 29'th Nov 2023
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
